LIC Buys More Cipla Shares as Stock Faces Headwinds

OTHER
Whalesbook Logo
AuthorAditi Singh|Published at:
LIC Buys More Cipla Shares as Stock Faces Headwinds
Overview

State-owned Life Insurance Corporation of India (LIC) has significantly increased its shareholding in Cipla Limited, raising its stake from 5.025% to 7.055% through market purchases between July and November 2025. This move by India's largest institutional investor signals growing confidence in the pharmaceutical major, even as Cipla navigates a challenging market characterized by margin pressures and declining sales of key products like gRevlimid.

Financial Deep Dive

Life Insurance Corporation of India (LIC), the nation's largest institutional investor, has substantially boosted its stake in pharmaceutical major Cipla Limited. Between July 17 and November 27, 2025, LIC acquired approximately 1.64 crore shares, marking a 2.03% increase in its holding. This acquisition has raised LIC's total stake in Cipla from 5.025% to 7.055%. The transactions were executed through open market purchases on the stock exchanges, adhering to SEBI's (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

The Numbers:

  • Previous Holding: 5.025% (approx. 4.06 crore shares)
  • New Holding: 7.055% (approx. 5.70 crore shares)
  • Shares Acquired: Approximately 1.64 crore shares
  • Acquisition Period: July 17, 2025 - November 27, 2025

This significant accumulation of shares by LIC comes at a time when Cipla's stock has faced considerable pressure. While the exact purchase price details for each transaction are not disclosed in the filing, reports indicate that LIC may have used Cipla's stock dips as an entry point.

The Backstory

LIC's increased investment marks a notable shift from its past holdings in Cipla. Over a decade ago, between August 2012 and January 2013, LIC had reduced its stake in Cipla from 8.34% to 6.21% by selling shares worth ₹665.39 crore. The current move signifies a renewed and increased conviction in Cipla's long-term prospects by the insurance behemoth.

Cipla's Performance and Market Position

Cipla, a leading player in the Indian pharmaceutical sector, is navigating a complex environment. While the company reported a modest 4% year-on-year growth in net profit to ₹1,351 crore on an 8% revenue increase to ₹7,589 crore for the second quarter of fiscal year 2026, its third-quarter performance showed a significant 57% year-on-year decline in net profit to ₹676 crore, impacted by lower sales of gRevlimid in North America.

EBITDA margins have also come under pressure, with forecasts suggesting further declines in FY26 and FY27 due to the phasing out of the key gRevlimid product. Despite these headwinds, Cipla maintains its leadership position in the respiratory segment, holding the #1 brand for Foracort, and has a strong presence in the Indian market with double-digit growth in branded prescriptions. The company has also received approval for Afrezza, an inhaled insulin, and is focusing on upcoming product launches to drive future growth.

Risks and Outlook

Cipla faces ongoing challenges including US pricing pressures, increased competition in generics, and the impact of product lifecycle changes, particularly the decline of gRevlimid sales. Analysts have also expressed caution, with some downgrading the stock. For instance, MarketsMOJO downgraded Cipla from 'Hold' to 'Sell' citing concerns over near-term performance and valuation, noting a one-year stock return of -7.93% compared to the Sensex's positive return. The company's EBITDA margin is projected to decline in the coming fiscal years, requiring a strong focus on cost optimization and operational efficiency.

Peer Comparison

The Indian pharmaceutical sector is broadly outperforming, with the Nifty Pharma index showing gains. Major players like Lupin, Biocon, and Torrent Pharmaceuticals are exhibiting strength, capitalizing on emerging therapy areas and biosimilars. Sun Pharmaceutical, Dr. Reddy's Laboratories, and Divi's Laboratories remain significant competitors. While Cipla holds leadership in respiratory therapies, it faces competition from players like Glenmark and USV in other segments. The overall sector faces headwinds from US pricing pressures and intense competition, making stock-specific analysis crucial.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.